ArticleJournal of medicinal chemistry2026

Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.

Justin A Shapiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.